Gynecologic Oncology Clinical Trials

Ovarian, Fallopian-Tube, or Peritoneal (Recurrent Platinum-Resistant or Refractory)


A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)              

Learn more.

Early-Stage Cervical Post-Hysterectomy (Adjuvant)


Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy             

Learn more.

Early-Stage Cervical Post-Hysterectomy (Adjuvant)


Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Learn more.

Locally Advanced Squamous Cell Carcinoma of the Vulva


A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva   

Learn more.

Newly diagnosed Cervical or Vaginal Cancer


A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer          

Learn more.

Recurrent Carcinoma of the Uterine Corpus


A Randomized Trial of Pelvic Irradiation +/_ Concurrent Weekly Cisplatin in Patients with Pelvic Only Recurrence of Uterine Carcinoma

Learn more.

Recurrent, Persistent or Metastatic Endometrial Cancer


A Randomized Phase 2 Study comparing Single Agent Olaparib, Single Agent Cediranib and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent, or Metastatic Endometrial Cancer

Learn more.

Need assistance?

Contact us